In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 2, 2006, Pages 288-293

  Lewis, Russell E ^a,b   Wiederhold, Nathan P ^c,d   Prince, Randall A ^a,b   Kontoyiannis, Dimitrios P ^a,b  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Candida albicans; Candida lusitaniae; Protein binding

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; HUMAN SERUM ALBUMIN;

ARTICLE; BOLUS INJECTION; CANDIDA ALBICANS; CANDIDA LUSITANIAE; CANDIDIASIS; COMPARTMENT MODEL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG METABOLISM; DRUG PROTEIN BINDING; FUNGICIDAL ACTIVITY; HUMAN; IN VITRO STUDY; NEPHROTOXICITY; NONHUMAN; PHARMACODYNAMICS; RAPID INFUSION; SIMULATION; STEADY STATE;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; CANDIDA; CANDIDIASIS; DEOXYCHOLIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; SERUM ALBUMIN;

EID: 31544482193     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki467     Document Type: Article

References (24)

1. Chabot GG, Pazdur R, Valeriote FA et al. Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. J Pharm Sci 1989; 78: 307-10.
2. Furrer K, Schaffner A, Vavricka SR et al. Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in ailogenic stem cell transplantation. Swiss Med Wkly 2002; 132: 316-20.
3. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: An open-label observational study. Clin Infect Dis 2003; 36: 943-51.
4. Peleg AY, Woods ML. Continuous and 4 h infusion of amphotericin B: A comparative study involving high-risk haematology patients. J Antimicrob Chemother 2004; 54: 803-8.
5. Speich R, Dutly A, Naef R et al. Tolerability, safety and efficacy of conventional amphotericin B administered by 24-hour infusion to lung transplant recipients. Swiss Med Wkly 2002; 132: 455-58.
6. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: Randomised controlled trial. BMJ 2001; 322: 579-82.
7. Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 2001: 45: 922-26.
8. Andes D. Clinical pharmacodynamics of antifungals. Infect Dis Clin North Am 2003; 17: 635-49.
9. Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 2003; 47: 1179-86.
10. Hiemenz JW. Amphotericin B deoxycholate administered by continuous infusion: Does the dosage make a difference? Clin Infect Dis 2003: 36: 952-53.
11. Bekersky I, Fielding RM, Dressier DE et al. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2003; 46: 834-40.
12. Atkinson AJ Jr, Bennett JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 1978; 13: 271-76.
13. Schmidt S, Muller RH. Plasma protein adsorption patterns on surfaces of Amphotericin B-containing fat emulsions. Int J Pharm 2003; 254: 3-5.
14. Lewis RE, Wiederhold NP. The solubility ceiling: A rationale for continuous infusion amphotericin B therapy? Clin Infect Dis 2003; 37: 871-72.
15. Pietrucha-Dilanchian P, Lewis RE, Ahmad H et al. Candida lusitaniae catheter-related sepsis. Ann Pharmacother 2001; 35: 1570-74.
16. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved Standard M27-A2. NCCLS, Wayne, PA, USA, 2002.
17. Klepser ME, Ernst EJ, Lewis RE et al. Influence of test conditions on antifungal time-kill curve results: Proposal for standardized methods. Antimicrob Agents Chemother 1998; 42: 1207-12.
18. Lewis RE, Kontoyiannis DP, Darouiche RO et al. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection. Antimicrob Agents Chemother 2002; 46: 3499-505.
19. Lewis RE, Lund BC, Klepser ME et al. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob Agents Chemother 1998; 42: 1382-86.
20. Shadomy S, Espinel-Ingroff A, Cartwright Y. Laboratory studies with antifungal agents: Susceptibility tests and bioassays. American Society for Microbiology, Washington, DC, USA, 1985.
21. Zhanel GG, Saunders DG, Hoban DJ et al. Influence of human serum on antifungal pharmacodynamics with Candida albicans. Antimicrob Agents Chemother 2001; 45: 2018-22.
22. Wiederhold NP, Kontoyiannis DP, Tam VH et al. Relationship between interferon-gamma (IFN-γ)/interleukin-10 (IL-10) and mycological efficacy of amphotericin B deoxycholate (AMBd) in invasive pulmonary aspergillosis (IPA). In: Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract M-230, p. 401. American Society for Mircobiology, Washington, DC, USA.
23. Collette N, Van der Auwera P, Meunier F et al. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J Antimicrob Chemother 1991; 27: 535-48.
24. Christiansen KJ, Bernard EM, Gold JW et al. Distribution and activity of amphotericin B in humans. J Infect Dis 1985; 152: 1037-43.